Abstract
The in vitro effect mediated by carbimazole (CBZ), a classical anti-thyroid agent on the antibody dependent cellular cytotoxicity (ADCC), low affinity E-rosetting cells (E-RFC) and high affinity E-RFC was investigated using lymphocytes from 11 normal subjects. CBZ at the doses of 250 and 500 μmol/l significantly reduced ADCC in all subjects studied. Low affinity E-RFC — mainly cells possessing receptors for the Fc portion of IgG and expressing cytotoxic properties in the ADCC system — were also significantly reduced following incubation with the same CBZ doses. These results suggest that CBZ, in addition to the known inhibitory effect on thyroid hormone synthesis, maybe useful by depressing lymphocyte cytotoxicity in the treatment of autoimmune thyroid disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Michie W.J.C., Beck R.G., Mahaffy E.F., Honein J.L, Fowler G.B. Quantitative, radiological and histological studies of the thymus in thyroid disease. Lancet 1: 691, 1967.
Wall J.R., Manwar G.L., Greenwood D.M., Walters B.A. The in vitro suppression of lectin induced 3H-thymidine incorporation into DNA of peripheral blood lymphocytes after the addition of propylthiouracil. J. Clin. Endocrinol. Metab. 43: 1406, 1976.
De Groot L.J. Short-term antithyroid drug therapy. N.Engl. J. Med. 297: 212, 1977.
Mc Gregor A.M., McLachlan S.M., Rooke P., Rees Smith B., Hall R. The influence of methimazole on the thyroidal autoimmune response in vitro. VIII Intern. Thyroid Congress. Sidney, February 3–8, 1980 (Abstract 78).
Pinchera A., Liberti P., Martino E., Fenzi G.F., Grasso L., Rovis L., Baschieri L., Doria G. Effects of antithyroid therapy on the long-acting thyroid stimulator and the antithyroglobulin antibodies. J. Clin. Endocrinol. Metab. 29: 231, 1969.
Beck J.S., Young R.J., Simpson J.G., Gray A.S., Nicol A.G., Pegg C.A.S., Michie W.J.C. Lymphoid tissue in the thyroid gland and thymus of patients with primary thyrotoxicosis. Br. J. Surg. 60: 769, 1973.
Hallengren B., Forsgren A., Melander A. Effects of antithyroid drugs on lymphocyte function in vitro. J. Clin. Endocrinol. Metab. 51: 298, 1980.
Pozzilli P., Sensi M., Gorsuch A.N., Bottazzo G.F., Cudworth A.G. Evidence for raised K cell levels in type 1 diabetes. Lancet 2: 173, 1979.
Pozzilli P., Andreani D., Sensi M., Wolf E., Taylor M., Bottazzo G.F., Cudworth A.G. K cells and antibody dependent cytotoxicity in autoimmune polyendocrine disease. VI Internal Congr. Endocrinology. Melbourne, February 10–16, 1980 (Abstract 639).
Calder E.A., Irvine W.J., Davidson M.D., Wu F. T, B and K cells in autoimmune thyroid disease. Clin. Exp. Immunol. 25: 17, 1976.
West W.H., Boozer R.B., Herberman R.B. Low affinity E-rosette formation by the human K cells. J. Immunol. 120: 90, 1978.
Sensi M., Pozzilli P., Gorsuch A.N., Bottazzo G.F., Cudworth A.G. Increased killer cell activity in insulin dependent (Type 1) diabetes. Diabetologia 20: 106, 1981.
Waller C.A., MacLennan I.C.M. Analysis of lymphocytes in blood and tissues. In: Thompson R.A. (Ed.), Techniques in clinical immunology. Blackwell, London, 1977, p. 170.
West W.H., Payne S.M., Weese J.L., Herberman R.B. Human lymphocyte subpopulations: correlation between E-rosette forming affinity and expression of Fc receptors. J. Immunol. 779: 548, 1977.
Pozzilli, P., Sensi M., Dean B., Gorsuch A.N., Cudworth A.G. The importance of measuring Fc+ (killer) cells in insulin dependent (type I) diabetes. Acta Diabetol. Lat. 17: 119, 1980.
Pozzilli P., Sensi M., Meschini C., Montano S., Andreani D. Low affinity and high affinity E-rosetting cells: a study with the 3A1 monoclonal antibody. IRCS Med. Sci. 9: 1047, 1981.
Fauci A.S. Immunoregulation in autoimmunity. J. Allergy Clin. Immunol. 66: 517, 1980.
Saal J.G., Rieber E.P., Hadam M., Riethmuller G. Lymphocytes with T-cell markers cooperate with IgG antibodies in the lysis of human tumour cells. Nature 265: 158, 1977.
Moretta L., Moretta A., Canonica G.W., Bacigalupo A., Mingari M.C., Cerottini J.C. Receptors for immunoglobulins on resting and activated human T cells. Immunological Rev. 56: 141, 1981.
Wise P.H., Marion M., Pain R. Mode of action of carbimazole in Graves’ disease. Clin. Endocrinol. (Oxf.) 10: 655, 1979.
Danenberg P.V. Thymidylate synthetase — a target enzyme in cancer chemotherapy. Biochim. Biophys. Acta 473: 73, 1977.
Sitar D.S., Hunninghake D.B. Pharmacokinetics of propylthiouracil in man after a single oral dose. J. Clin. Endocrinol. Metab. 40: 26, 1975.
Marchant B., Alexander W.D., Lazzarus J.H., Lees J., Clark D.M. The accumulation of 35S-antithyroid drugs by the thyroid gland. J. Clin. Endocrinol. Metab. 34: 847, 1972. ai]24._Pinchera A., Rovis L., Davoli C., Grasso L., Baschieri L. Lats and Graves’ disease: clinical and radioimmunological studies. In: Mattar E., De Brong Mattar G., James V.H.T. (Eds.), Recent advances in endocrinology. Excerpta Medica Internat. Congress series no. 238, Amsterdam, 1971, p. 91.
Doniach D. Hashimoto’s thyroiditis and primary myxoedema viewed as separate entities. Eur. J. Clin. Invest. 11: 245, 1981.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pozzilli, P., Sensi, M. & Andreani, D. Inhibition of killer cell cytotoxicity induced by carbimazole in vitro . J Endocrinol Invest 5, 149–152 (1982). https://doi.org/10.1007/BF03349469
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03349469